| Annual Financials | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 187 | 172 | 227 | 263 | 282 | 276 | 278 |
| Expenses | 147 | 133 | 173 | 206 | 223 | 215 | 217 |
| EBITDA | 40 | 39 | 54 | 56 | 59 | 61 | 61 |
| Operating Profit % | 20 % | 22 % | 23 % | 20 % | 21 % | 22 % | 22 % |
| Depreciation | 17 | 17 | 17 | 18 | 20 | 18 | 19 |
| Interest | 38 | 40 | 49 | 35 | 34 | 28 | 24 |
| Profit Before Tax | -15 | -18 | 62 | 3 | 5 | 15 | 19 |
| Tax | 4 | 4 | 7 | 5 | 2 | 4 | 7 |
| Net Profit | -19 | -22 | 55 | -2 | 4 | 11 | 13 |
| EPS in ₹ | -7.04 | -8.14 | 20.54 | -0.79 | 1.35 | 3.71 | 13.00 |
Amanta Healthcare
Amanta Healthcare
110.80
-2.16
(-1.91%)
Market Cap
₹430.23 Cr
PE Ratio
33.92
Volume
1,94,184.00
Day High - Low
₹118.75 - ₹108.50
52W High-Low
₹154.40 - ₹110.20
Key Fundamentals
Market Cap
430.23 Cr
EPS
3.71
PB Ratio
2.14
Book Value
54.26
EBITDA
61.10
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
2.12
Actual
Company News
View All News
Amanta Healthcare utilized Rs 3,030.02 lakhs from its Rs 12,600 lakhs IPO proceeds during the quarter ended September 30, 2025, primarily for capital expenditure on manufacturing equipment and civil construction work. The pharmaceutical company has Rs 9,569.98 lakhs remaining for planned expansion of SteriPort and SVP manufacturing lines at its Gujarat facility, with production expected to commence from January 2026 and 2027 respectively.
Amanta Healthcare Limited filed a statement of deviation in fund utilization for the quarter ended September 30, 2025. The company raised Rs 126 crore through its IPO. The deviation occurred due to GST payment modifications over the costs mentioned in the IPO Offer Document, which resulted in adjustments to issue expenses and a corresponding reduction in general corporate purpose expenses. The company allocated funds for capital expenditure requirements including civil construction work and purchase of equipment for setting up new manufacturing lines - Rs 7000 lakhs for SteriPort at Hariyala, Kheda, Gujarat (with Rs 764.81 lakhs utilized) and Rs 3013.11 lakhs for SVP manufacturing line at the same location. General corporate purposes allocation was modified from Rs 660.46 lakhs to Rs 302.08 lakhs. Issue expenses were adjusted from Rs 1926.43 lakhs to Rs 2284.81 lakhs with Rs 2265.21 lakhs utilized. The Audit Committee reviewed the statement and provided no comments.
Amanta Healthcare Limited's Board of Directors approved the company's standalone unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported total income of Rs 7,095.80 lakhs for the quarter and Rs 13,850.45 lakhs for the six-month period. Net profit for the quarter was Rs 207.8 lakhs and Rs 185.50 lakhs for the half-year. The company completed its Initial Public Offering (IPO) during the quarter, issuing 10,000,000 equity shares at Rs 126 per share, raising Rs 12,600 lakhs. The equity shares were listed on BSE Limited and National Stock Exchange of India Limited on September 9, 2025. IPO-related expenses of Rs 262.88 lakhs were recognized as an exceptional item. The company operates in pharmaceutical manufacturing and contract manufacturing services. PriceWaterhouseCoopers provided an unmodified review opinion on the financial results.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,810.30 | #1 4,34,351.61 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 76.30 | |
6,490.50 | 1,72,302.38 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.50 | |
3,730.40 | 1,26,253.69 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 54.46 | |
1,525.20 | 1,23,198.65 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.61 | |
1,249.30 | 1,04,268.30 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 53.75 | |
2,071.40 | 94,612.13 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 63.44 | |
937.25 | 94,309.28 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 41.16 | |
2,249.30 | 92,841.77 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 38.34 | |
1,235.80 | 71,775.46 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 67.24 | |
5,686.50 | 67,990.64 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.98 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-1.95 %
Net Income Growth
191.67 %
Cash Flow Change
-19.72 %
ROE
98.72 %
ROCE
2.63 %
EBITDA Margin (Avg.)
5.99 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 388 | 392 | 392 | 374 | 352 | 382 |
| Fixed Assets | 244 | 242 | 240 | 232 | 228 | 217 |
| Current Assets | 105 | 131 | 136 | 131 | 118 | 138 |
| Capital Work in Progress | 0 | 0 | 0 | 9 | 0 | 7 |
| Investments | 0 | 2 | 3 | 0 | 4 | 8 |
| Other Assets | 144 | 149 | 149 | 133 | 120 | 150 |
| Total Liabilities | 388 | 392 | 392 | 374 | 352 | 382 |
| Current Liabilities | 73 | 123 | 106 | 97 | 102 | 115 |
| Non Current Liabilities | 285 | 262 | 214 | 214 | 184 | 170 |
| Total Equity | 29 | 7 | 72 | 63 | 66 | 96 |
| Reserve & Surplus | 2 | -20 | 36 | 36 | 40 | 68 |
| Share Capital | 27 | 27 | 37 | 27 | 27 | 29 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -8 | -0 | 6 | -6 | 1 | -1 |
| Investing Activities | -9 | -13 | -6 | -7 | -10 | -25 |
| Operating Activities | 38 | 31 | 62 | 43 | 58 | 47 |
| Financing Activities | -37 | -18 | -50 | -42 | -46 | -24 |
Share Holding
| % Holding | Sept 2024 | Feb 2025 | Jun 2025 | Aug 2025 | Sept 2025 |
| Promoter | 85.52 % | 85.52 % | 63.56 % | 85.60 % | 63.56 % |
| FIIs | 0.00 % | 0.00 % | 2.21 % | 0.00 % | 1.00 % |
| DIIs | 0.00 % | 0.00 % | 12.22 % | 0.00 % | 11.34 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 0.00 % | 20.28 % | 0.00 % | 17.35 % |
| Others | 14.48 % | 14.48 % | 1.74 % | 14.40 % | 6.75 % |
| No of Share Holders | 192 | 200 | 30,695 | 361 | 360 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 26 Sept 2025 |  Quarterly Result Announcement | NA | 26 Sept 2025 | 140.05 | 139.35 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 122.15 | 120.30 |
Announcements
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Nov 14, 2025
Nov 14, 2025Re Submission Of Financial Results For Quarter And Half Year Ended September 30 2025.Nov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Nov 13, 2025Re-Constitution Of Audit CommitteeNov 12, 2025
Nov 12, 2025Statement Of Deviation And VariationNov 11, 2025
Nov 11, 2025To Approve Unaudited Financial Results For Q2 Of FY 2025-26Nov 11, 2025
Nov 11, 2025Board Meeting Outcome for To Approve Unaudited Financial Results For Q2 Of FY 2025-26Nov 11, 2025
Nov 11, 2025Board Meeting Intimation for To Approve Unaudited Financial Results For Quarter Ended September 30 2025Nov 03, 2025
Nov 03, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Oct 07, 2025Intimation Of Change In E-Mail Address Of Registrar And Share Transfer Agent (RTA) Of The CompanyOct 04, 2025
Oct 04, 2025Intimation Of Redemption Of Unlisted 10000000 (One Crore) 14% Non-Convertible Cumulative Participating Redeemable Preference Shares (RPS) Of Face Value Of Rs.10/-Sep 29, 2025
Sep 29, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 27, 2025
Sep 27, 2025Board Meeting Outcome for To Approve Unaudited Financial Result For Q1 Of 2025-26Sep 26, 2025
Sep 26, 2025Result - Financial Results For Q1 Of 2025-26Sep 26, 2025
Sep 26, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations)Sep 26, 2025
Sep 26, 2025Board Meeting Intimation for Inter-Alia To Consider And Approve Unaudited
Financial Results Of The Company For The Quarter Ended 30Th June 2025Sep 18, 2025
Sep 18, 2025Closure of Trading WindowSep 12, 2025
Sep 12, 2025Listing of Equity Shares of Amanta Healthcare LtdSep 09, 2025
Sep 09, 2025Mutual Fund Holdings
| Funding House | Current Holding % | 1M Change | 1M Change % | 3M Change % | Last 6M Trend |
|---|---|---|---|---|---|
 Bandhan Small Cap Fund Direct-Growth | 0.08% | 138376 | 0.00% | 0.01% |
Technical Indicators
RSI(14)
Neutral 34.62
ATR(14)
Less Volatile 4.46
STOCH(9,6)
Oversold 18.25
STOCH RSI(14)
Oversold 10.24
MACD(12,26)
Bearish -0.36
ADX(14)
Strong Trend 36.92
UO(9)
Bearish 42.63
ROC(12)
Downtrend And Accelerating -5.99
WillR(14)
Oversold -81.21
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
